Geron Corp (GON.BE)
- Zacks
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of 10% and 102.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
FOSTER CITY, Calif., May 02, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results and business highlights for the first quarter 2024.
- Business Wire
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
FOSTER CITY, Calif., April 25, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day.
